India’s hair-growth market is projected to double to US$546 million by 2028
Hair-loss brands including Traya and Man Matters are targeting younger consumers with diagnosis-led regimens, while transplants and hair toppers broaden the category. Redseer estimates the US$270 million market will grow at a 15% CAGR through 2028.
The brand move
India's hair-management market is shifting toward diagnosis-led, long-duration treatments, transplants and aspirational hair toppers. Redseer estimates the US$270 million hair-growth category will reach US$546 million by 2028, while brands target younger, digitally informed consumers.
The numbers
- 82 million urban Indians experience hair loss
- Around 5 million people currently use an OTC or retail hair-loss product
- India hair-growth market: US$270 million
- Hair-growth market CAGR: 15%
- Projected hair-growth market by 2028: US$546 million
- Man Matters consultations up 62% year over year
- Traya study covered more than 500,000 Indian men; 50% of those with hair loss are under 25
- Men's topper market estimated at Rs 1,300 crore
- Women's topper market estimated at Rs 500 crore
- Topper markets growing around 15% annually
- 1 Hair Stop patches: Rs 1,200-Rs 20,000
- 1 Hair Stop toppers: Rs 1,500-Rs 1.5 lakh
- 1 Hair Stop full wigs: Rs 1.2 lakh-Rs 4 lakh
Why it matters for the brand
Strategic buyers should look for partnerships or acquisitions in diagnostic platforms, telehealth-led hair-loss brands, transplant networks, and hair-topper specialists to build an end-to-end hair-management portfolio.
What to track next
- Growth in repeat purchase and six-month regimen completion rates among Traya, Man Matters and comparable platforms.
- Customer-acquisition-cost inflation across Meta, Google and influencer channels for hair-loss keywords and creators.
- Expansion of teledermatology rules, prescription controls or advertising enforcement around hair-loss and nutraceutical claims.
- Clinic and transplant-chain expansion, financing offers and partnerships between digital hair brands and offline providers.
- Search and social demand shifting from 'hair fall shampoo' toward 'hair regrowth,' 'minoxidil,' 'hair transplant' and cosmetic concealment terms.
- Mass FMCG and pharmacy brands launching diagnosis tools, subscription plans or clinically positioned anti-hair-loss ranges.
- Build a tiered portfolio spanning entry-level diagnostic kits, recurring treatment regimens and high-ticket clinic, transplant or hair-topper referrals.
- Measure cohort retention by diagnosis type, age group and regimen adherence; optimize for six- and twelve-month value rather than first-order conversion.
- Use diagnosis data to create adjacent offers in scalp care, stress management, nutrition, dermatology and post-treatment maintenance.
- Develop offline trust points through dermatologist networks, clinic partnerships, pharmacy distribution and transplant-center referral programs.
- Strengthen clinical substantiation, consent flows and claims review before scaling youth-focused advertising.
- Prepare value-oriented bundles and refill plans as consumers trade down in discretionary beauty spending while preserving treatment continuity.
The counter-case
The projection may overstate durable demand by conflating recurring hair-loss treatment, one-off transplants, cosmetic toppers and adjacent OTC products into a single expanding market. Younger consumers may try diagnosis-led subscriptions but churn quickly when results are slow, uncertain or require lifelong treatment. Rising customer-acquisition costs, skepticism around digital consultations, clinical-claim scrutiny and price sensitivity could limit profitable growth even if category sales rise.